Tucotuzumab celmoleukin
As of the edition of 20 October 2026, Tucotuzumab celmoleukin is an antibody drug conjugate: went quiet in 2009; acts on EPCAM.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Went quiet, 2009
- Kind
- Antibody drug conjugate
- Registered trials
- 3, 1 stopped early
- Disease areas
- Cancer; Pregnancy and women's health; Urinary and reproductive; Hormones; Lungs and airways; Digestive system
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
1 company on route A because of this drug.
Companies on route A for this drug
In the product1 company is on route A because of Tucotuzumab celmoleukin.
See the 1 company on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| EPCAM | Epithelial cell adhesion molecule | P16422 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 2 | 2 | 0 | 0 |
| Phase 2 | 1 | 0 | 0 | 1 |
| All trials | 3 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Merck KGaA | Lead sponsor of trials | 2000 to now |